Boule Diagnostics AB risk profile
51 Elevated one input has moved against it
Measured 1 September 2026 from BOUL's filed statements. Recomputed nightly.
51 (Elevated), driven by Operating pressure at 81, over 4 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 80 | Acute | Volatile | Drawdown from the 52-week high — 51.7% |
| Operating pressure | 81 | Acute | Worsening | Costs outgrowing revenue — +66.6 percentage points |
| Cash conversion | 32 | Normal | Worsening | Capital spending against operating cash — 0.19x |
| Leverage and coverage | Reads total_debt, cash_and_cash_equivalents, ebitda, interest_expense, total_current_assets, total_current_liabilities and a disclosed CET1 ratio, for a bank or insurer. No reading is stored for this company. | |||
| Competitive position | 33 | Normal | Stable | R&D-intensity gap against peers — -23.4 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for Boule Diagnostics AB